Author

B. Teicher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. B. Radaoui· 1 shared A. Delaidelli· 1 shared A. K. Weiner· 1 shared A. Luna· 1 shared A. Modi· 1 shared A. Thomas· 1 shared B. A. Garcia· 1 shared B. Ennis· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. Radaoui

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

A. K. Weiner, A. B. Radaoui, M. Tsang, D. Martinez, S. Sidoli, K. L. Conkrite, A. Delaidelli, A. Modi, J. L. Rokita, K. Patel, M. V. Lane, B. Zhang, C. Zhong, B. Ennis, D. P. Miller, , S. J. Diskin

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

bioRxiv · Dec 6, 2023 · PreprintCancer Biology

SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures

C. Tlemsani, L. Pongor, L. Girard, N. Roper, F. Elloumi, S. Varma, A. Luna, V. N. Rajapakse, R. Sebastian, K. W. Kohn, J. Krushkal, M. Aladjem, B. Teicher, P. S. Meltzer, W. C. Reinhold, , Y. Pommier

SCLC_CellMiner provides an integrated resource of 118 SCLC cell lines with omics data and drug sensitivity, identifying molecular subtypes and therapeutic targets.

bioRxiv · Mar 9, 2020 · PreprintCancer Biology